Pfizer: Still Not Enough Lipitor/Diabetes Cases To Justify An MDL

Pfizer: Still Not Enough Lipitor/Diabetes Cases To Justify An MDL

WASHINGTON, D.C. - Pfizer Inc. on Nov. 1 opposed a renewed motion to create a multidistrict litigation for federal Lipitor/diabetes lawsuits, saying there are still not enough cases to justify centralization (In Re: Lipitor [Atorvastatin Calcium] Marketing, Sales Practices and Products Liability Litigation [No. II], MDL Docket No. 2501, JPMDL).

Find full version on lexis Advance®
Access this news story on lexis.com®